Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry


ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

Major Highlights of the CAR-TCR Summit, Boston, 2016

Author(s): Vita Golubovskaya*, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu*

Volume 17, Issue 10, 2017

Page: [1344 - 1350] Pages: 7

DOI: 10.2174/1871520617666170110151900

Price: $65


Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.

Keywords: Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy